GDC-0570
GDC-0570 is a novel, potent, selective, orally active pan-PIM inhibitor. GDC-0570 demonstrates synergistic antitumor efficacy when combined with Sotorasib (HY-114277) in acquired KRASis-resistant NSCLC.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1586041-58-8
- Formule: C20H20F3N5O2S
- Masse moléculaire:451.47
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1586041-58-8
-
Masse moléculaire 451.47
-
Formule C20H20F3N5O2S
-
SMILES
O=C(C1=CSC(C2=C(C=CC=C2F)F)=N1)NC3=C([C@@H]4CC[C@H]([C@@H](CO4)F)N)N(N=C3)C
-
Synonyms
NB004
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)